Trials / Active Not Recruiting
Active Not RecruitingNCT02157324
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acalabrutinib | |
| DRUG | ACP-319 |
Timeline
- Start date
- 2014-08-18
- Primary completion
- 2020-07-20
- Completion
- 2026-04-01
- First posted
- 2014-06-06
- Last updated
- 2025-08-13
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02157324. Inclusion in this directory is not an endorsement.